CLAIMS

1. A pharmaceutical composition comprising, based on the total weight of the composition:
55.0 wt% to 75.0 wt% of lanifibranor; and
25.0 wt% to 45.0 wt% of pharmaceutically acceptable excipients;
wherein lanifibranor has a particle size distribution such that D50 ≤ 30 µm and D90 ≤ 50 µm, preferably D50 ≤ 10 µm and D90 ≤ 30 µm.

2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition releases from about 30 to 60% of lanifibranor within 15 minutes after oral ingestion.

3. The pharmaceutical composition of any one of claims 1 to 2, wherein said pharmaceutical composition releases at least 80% of lanifibranor within 45 minutes after oral ingestion.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutically acceptable excipients include two or more of a binder, a colouring agent, a disintegrant, a filler, a glidant, a lubricant, a preservative, a surfactant, and a sweetener.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutically acceptable excipients include a filler, and the filler represents from 10.0 wt% to 35.0 wt% of the total weight of the composition.

6. The pharmaceutical composition of claim 5, wherein the filler is selected from lactose monohydrate, lactose anhydrous, starch, modified starch, mannitol and mixtures thereof.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutically acceptable excipients include a surfactant, and the surfactant represents from 1.0 wt% to 5.0 wt% of the total weight of the composition.

8. The pharmaceutical composition of claim 7, wherein the surfactant is selected from non-ionic surfactants, anionic surfactants, cationic surfactants, and mixtures thereof.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the pharmaceutically acceptable excipients include a binder, and the binder represents from 1.0 wt% to 10.0 wt% of the total weight of the composition.

10. The pharmaceutical composition of claim 9, wherein the binder is selected from cellulose, modified cellulose, microcrystalline cellulose, polyvinylpyrrolidone and mixtures thereof.

11. The pharmaceutical composition of any one of claims 1 to 10, wherein the pharmaceutically acceptable excipients include a lubricant, and the lubricant represents from 0.5 wt% to 5.0 wt% of the total weight of the composition.

12. The pharmaceutical composition of claim 11, wherein the lubricant is selected from talc, stearic acid, magnesium stearate, calcium stearate, sodium sterayl fumarate, silica gel and mixtures thereof.

13. The pharmaceutical composition of any one of claims 1 to 12, wherein the pharmaceutically acceptable excipients include a disintegrant, and the disintegrant represents from 1.0 wt% to 8.0 wt% of the total weight of the composition.

14. The pharmaceutical composition of claim 13, wherein the disintegrant is selected from starch, modified starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and mixtures thereof.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutically acceptable excipients include a glidant, and the glidant represents from 0.1 wt% to 5.0 wt% of the total weight of the composition.

16. A pharmaceutical composition as defined in any one of claims 1 to 15, comprising, based on the total weight of the composition:

- from 55.0 wt% to 75.0 wt% of lanifibranor,
- from 10.0 wt% to 35.0 wt% of filler;
- from 1.0 wt% to 5.0 wt% of surfactant;
- from 1.0 wt% to 10.0 wt% of binder;
- from 0.5 wt% to 5.0 wt% of lubricant;
- from 1.0 wt% to 8.0 wt% of disintegrant;
- from 0.1 wt% to 5.0 wt% of glidant.

17. The pharmaceutical composition of any one of claims 1 to 16, which is a solid dosage form.

18. The pharmaceutical composition of claim 17, which is a tablet, a capsule or a stick-pack, preferably a tablet.

19. The pharmaceutical composition of claim 17 or claim 18, which comprises from 200 mg to 1,200 mg of lanifibranor.

20. The pharmaceutical composition of any one of claims 1 to 19, wherein lanifibranor is in crystalline form.

21. Use of a pharmaceutical composition as defined in any one of claims 1 to 20, in the manufacture of a medicament for treating a cirrhotic subject at risk of progressing from compensated stage to decompensated stage.

22. Use of a pharmaceutical composition as defined in any one of claims 1 to 20, in the manufacture of a medicament for treating cirrhosis, liver fibrosis, liver steatosis, fatty liver disease, acute decompensation, acute on chronic liver failure, acute liver failure, decompensated cirrhosis, compensated cirrhosis, metabolic-associated fatty liver disease, metabolic-associated steatohepatitis, diabetes, or liver cirrhosis.